Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rechallenge Strategy in Cancer Therapy.
Hanovich E, Asmis T, Ong M, Stewart D. Hanovich E, et al. Among authors: asmis t. Oncology. 2020;98(10):669-679. doi: 10.1159/000507816. Epub 2020 Jun 29. Oncology. 2020. PMID: 32599578 Review.
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD; National Cancer Institute of Canada Clinical Trials Group. Asmis TR, et al. J Clin Oncol. 2008 Jan 1;26(1):54-9. doi: 10.1200/JCO.2007.12.8322. J Clin Oncol. 2008. PMID: 18165640 Clinical Trial.
Review of anal cancer patients at the Ottawa hospital.
Abunassar M, Reinders J, Jonker DJ, Asmis T. Abunassar M, et al. Among authors: asmis t. Eur J Surg Oncol. 2015 May;41(5):653-8. doi: 10.1016/j.ejso.2015.02.004. Epub 2015 Mar 4. Eur J Surg Oncol. 2015. PMID: 25776438
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
Moore M, Gill S, Asmis T, Berry S, Burkes R, Zbuk K, Alcindor T, Jeyakumar A, Chan T, Rao S, Spratlin J, Tang PA, Rothenstein J, Chan E, Bendell J, Kudrik F, Kauh J, Tang S, Gao L, Kambhampati SR, Nasroulah F, Yang L, Ramdas N, Binder P, Strevel E. Moore M, et al. Among authors: asmis t. Ann Oncol. 2016 Dec;27(12):2216-2224. doi: 10.1093/annonc/mdw412. Epub 2016 Oct 11. Ann Oncol. 2016. PMID: 27733377 Free article. Clinical Trial.
Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.
Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E; Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group. Singh S, et al. Among authors: asmis t. JAMA Oncol. 2018 Nov 1;4(11):1597-1604. doi: 10.1001/jamaoncol.2018.2428. JAMA Oncol. 2018. PMID: 30054622
76 results